Background: The aim was to define the MTD of topotecan (TPT) given before cisplatin in patients with previously untreated SCLC.
Introduction
Topotecan belongs to a novel class of anticancer drugs, the camptothecins. The sodium salt of camptothecin was evaluated in early clinical trials in the 1970s, but further clinical development was suspended due to unpredictable toxicity including haemorragic cystitis [1, 2] . Later, it was discovered that the camptothecins have a unique mechanism of action. These drugs kill cells by freezing an essential enzyme, topoisomerase I in a temporally state in which the topoisomerase I is bound to a broken piece of single-strand DNA [3] . When the DNA replication machinery encounters these topoisomerase I-bound DNA strand breaks they are converted to permanent and lethal DNA double-strand breaks [4, 5] . As a consequence, topotecan cytotoxicity is dependent on intracellular levels of topoisomerase I and the fraction of cells undergoing DNA synthesis.
Among the many new agents which underwent clinical evaluation in small-cell lung cancer (SCLC) in the last decade, topotecan was found to be one of the most active drugs [6, 7] , indicating a future role for topotecan in combination with established drugs in this disease entity. Preclinical studies indicated a synergistic tumor cell kill when cisplatin and topotecan are used in combination [8, 9] . This combination has been tested in a cisplatin on day 1 without growth factor support [10] , but later, the same group reported that 3 out 12 patients died of treatment related neutropenic sepsis using this schedule [11] . In order to increase the dose delivery of topotecan we chose to examine the alternate sequence of the drugs, i.e., cisplatin on day 5 preceded by five-day topotecan based on data by Rowinsky et al. indicating that cisplatin following topotecan was significantly less myelosuppressive than cisplatin given before topotecan [12] . However, the latter study was not designed to establish the MTD of the alternate sequence. In the present study, the topotecan-cisplatin based courses were given every second cycle. The alternate cycles consisted of a combination of cisplatin, carboplatin, teniposide and vincristine, corresponding to one of the arms in the most recent phase III trial at the participating institutions [13] . The rationale for this alternating schedule was two-fold. Firstly, topotecan-cisplatin as front-line treatment must be considered experimental therapy and we wanted to ensure that established treatment was delivered in reasonable doses early in the course of the treatment. Secondly, preclinical data indicate that sequential treatment with topoisomerase-I (topotecan) and -II (teniposide) inhibitors could prove beneficial, based on tumor cell studies showing that resistance towards one type of drug often confers hyper-sensitivity to the other drug type [8, 14, 15] . The mechanism behind this pattern might be that tumor cells in response to topotecan induced topoisomerase I downregulation compensate by up-regulating the target of teniposide-topoisomerase II [16] [17] [18] .
Patients and methods

Eligibility
Patients with histologically verified SCLC (WHO type II) or mixed histology (WHO type V) regardless of disease extent were candidates for the trial provided that they had measurable or evaluable disease, age between 18 and 70 years, WHO performance status of 0-2, and had not received prior radio-or chemotherapy. The following laboratory values were required at entry: hemoglobin level 3*6.0 mmol/1 (9.6 g/dl), white blood cell count SOOOO/ul, neutrophil count 3:1500/ul, platelet count ~z 100,000/ul, serum creatinine level <133 mmol/1 (1.5 mg/dl), sl Cr-EDTA clearance 5=60 ml/min, serum bilirubin level 34 mmol/1 (1.4 mg/dl), transaminases and alkaline phosphatase < 2 times the upper limit of normal or ^ 3 times the upper limit of normal in the presence of liver metastases. The protocol was approved by the local ethical committee. All patients gave written informed consent. Patients were ineligible if they had a history of prior or present malignancies other than SCLC except for carcinoma of the skin or CIS of the cervix, active non-controlled infection, a concurrent medical problem unrelated to their lung cancer which could significantly limit full compliance with the study or expose the patient to an undue risk of decreased life expectancy. Further, treatment with an investigational drug within 30 days prior to study entry was not allowed. No concurrent chemotherapy, immunotherapy, or investigational therapy for the treatment of SCLC were allowed. Radiotherapy could be administered if the clinical condition demanded it. Pregnant or lactating females were not allowed to enter the study.
Treatment
A total of six cycles of chemotherapy was scheduled for each patient. . All drugs were administered intravenously. Intervals between the treatment cycles were 21 days following cycle A and 28 days following cycle B. After the completion of chemotherapy, chest-and prophylactic cranial irradiation were allowed according to the guidelines at the participating institutions. Chest radiation was not performed concomitantly with chemotherapy to avoid radiation induced toxicity as the study aimed exclusively at assessing the toxicity of the combination of topotecan and cisplatin.
Drug administration
Topotecan was supplied as a lyophilized cake in 4 mg vials by SmithKline Beecham Pharmaceuticals, Welwlyn Garden City, UK. The drug was reconstituted with 2 ml of sterile water, diluted in 50 or 100 ml of normal saline and infused over 30 minutes. Cisplatin was infused over 30 minutes. A standard hydration regimen was used. Carboplatin was dosed according to Calverts equation using GFR monitored by Cr-EDTA clearance. Teniposide was infused over 30 minutes. Vincristine was given as a bolus.
In cycles A, prophylactic antiemetics included 30 mg metoclopramide or metopimazine orally 3-4 times daily day 1-4. On day 5 and the following morning, 8 mg oral ondansetron was administered twice Leucocyte count on day 1 < 3000/ul or neutrophil count on day I < 1500/ul or platelet count on day < 75,000/ul
One week delay Failure to recover after one week required dose reductions as outlined above daily in combination with a single oral dose of 50 mg prednisolone. In cycles B, the prophylactic antiemetic regimen was identical to that used on day 5 of cycles A.
Dose escalation
Only the doses of topotecan were escalated and no dose escalation in individual patients was allowed. All other drugs were given in a fixed dose unless toxicity required individual dose reductions. Cohorts of three patients were included at dose levels 0.75, 1.0, 1.25, and 1.5 mg/m 2 /d. If no patient experienced dose limiting toxicity (DLT), accrual was continued at the next dose level. If two out of three patients at a given dose level had DLT, accrual was to be discontinued and the dose level below was considered the maximal tolerable dose (MTD). If one out of three patients at a given dose level had DLT, an additional cohort of three patients had to be included at this dose level. If one or more patients in the second cohort had DLT, accrual was stopped and the dose level below was considered MTD. If none of the patients in the second cohort had DLT, dose escalation proceeded to next dose level. Decisions regarding dose escalation were based on toxicity data derived from the first course of topotecan/cisplatin. A minimum of six patients was to be treated at the dose level defined as MTD. When MTD was defined, we planned to transform the study to a phase II study with the aim of treating a total of 25 patients at MTD. The results of the latter trial will be reported later.
Toxicity was graded according to Guidelines for Reporting of Adverse Drug Reactions, Bethesda, Division of Cancer Treatment, National Cancer Institute, 1988. Dose limiting toxicity (DLT) was defined as toxicity after the first cycle of topotecan-cisplatin including one of the following: grade 3 or 4 non-hematological toxicity other than nausea, vomiting, fever, alopecia or anorexia; grade 4 neutropenia (^500/ul) lasting more than seven days or complicated with fever > 38.5 *C and/or infection; grade 4 thrombocytopenia (< 25,000/ul) of any duration; failure to recover neutrophil count 3= 1500/ul or platelet count 3= 75,000/ul by day 28.
Dose modifications
Dose reductions and decisions for treatment delay were based on the criteria outlined in Table 1 .
Patient evaluation and follow-up
Pretreatment evaluation included complete history, physical examination, WHO performance status, chest X-ray, chest, brain and abdominal CT scans, bronchoscopy including endobronchial biopsy, bilateral bone marrow aspirates and biopsies from the iliac crest, routine laboratory tests including hemoglobin, differential WBC, platelet count and chemistries (electrolytes, creatinine, albumin, prothrombin time, lactate dehydrogenase, alkaline phoshpatase, total bilirubin, alanine aminotransferase), electrocardiograms, urinanalysis, 5l Cr-EDTA clearance, and audiometry.
Complete blood cell count were performed on days 11 and 15. 51 Cr-EDTA clearance was performed before carboplatin based cycles. Chest X-ray and routine laboratory tests as outlined above were repeated before each treatment cycle. Tumor evaluation by CT scans of involved regions were repeated every second treatment cycles, i.e., every 7 weeks during treatment and hereafter every 4 months for 24 months.
Criteria for evaluation of tumor response and toxicity
Tumor response evaluation was done according to the WHO criteria.
Statistics
A multiple regression analysis with backward stepwise elimination was used to evaluate if toxicity increased as more cycles were administered. The cut off value for elimination was a significance level of 0.05. For the comparison of toxicity in cycles A and B non-parametric statistics were applied due to the small sample sizes. The Wilcoxon matched pairs test was used for continuous data and the McNemar test for binomial data. Cycles were compared in pairs as follows: cycle 1 to 2, cycle 3 to 4, and cycle 5 to 6. All p values are based on two-sided tests.
Results
Between November 1996 and July 1998, 22 patients entered the study at Finsen Centre, (n = 20) and as of April 1998 at Department of Oncology, Herlev (n -2), both Copenhagen. One patient assigned to dose level 1.5 mg/m 2 died suddenly before receiving any protocol specified treatment and was excluded for further analysis. Of the remaining 21 patients, 15 had limited and 6 had extensive disease. Patients were equally balanced between sexes (11 males and 10 females), and the majority had performance status (PS) one (PS 0, n -2; PS 1, n = 16; PS 2, n -3). Three, four and three patients were entered at dose levels 0.75, 1.0 and 1.25 mg/m 2 while eleven patients were treated at the highest dose level of 1.5 mg/m 2 . As the first patient on dose level 1.0 mg/m 2 suffered an early death due to tumor progression, additionally three patients were included on this dose level. Sixteen patients completed all six scheduled cycles of therapy. The remaining five patients discontinued treatment due to tumor progression (n -3) and toxicity in = 2).
Hematological toxicity
At dose levels 0.75 and 1.0 mg/m 2 , no grade 4 neutropenia was observed. At dose levels 1.25 and 1.5 mg/m 2 grade 4 neutropenia was recorded in approximately half of the delivered cycles (Table 2a) . No episodes of grade 4 neutropenia lasting more than seven days or grade 4 thrombocytopenia were observed after the first cycles A and accordingly 1.5 mg/m 2 was denned as MTD. However, grade 4 neutropenia of more than seven days duration occurred after the fifth cycle at dose level 1.5 (n -3) and 1.25 (n = 1) mg/m 2 (Table 2a) . Seven episodes of grade 4 thrombocytopenia followed cycles 3 and 5 (1 at 1.0 mg/m 2 ; 2 at 1.25 mg/m 2 ; 4 at 1.5 mg/m 2 ) (Table 2b ). Grade 3 anemia was observed in one case (not shown). No patients experienced sepsis, and neutropenia was associated with fever in one patient treated at 1.25 mg/m 2 following the last topotecan/cisplatin treatment cycle. No patients required dose reductions of topotecan. To determine if hematological toxicity increased with the number of cycles delivered, a multiple regression analysis was performed on hemoglobin values, neutrophil counts, and platelet counts at the time of nadir using dose, renal function ( 51 Cr-EDTA clearance) and cycle number as covariates. With respect to anemia and thrombocytopenia the dose could be eliminated in the model at a significance level of 0.05 whereas the number of cycles and renal function were independent predictors of nadir counts. In contrast, the number of cycles delivered was not an independent predictor of the nadir neutrophil count, indicating that the degree of neutropenia did not increase as more cycles were delivered to each patient. Similar analysis were performed for cycles 2, 4 and 6 (teniposide based cycles) showing that hematological toxicity did not increase with number of cycles administered.
Hematological toxicity following cycles B was as follows: Grade 4 neutropenia and thrombocytopenia occurred in 66% (Table 2a ) and 50% (Table 2b ) of cycles. Grade 3 and 4 anemia were observed in 6% of cycles (not shown). Seven episodes of grade 4 neutropenia lasting more than seven days were recorded (Table 2a) . No episodes of either treatment related deaths or sepsis occurred.
Paired non-parametric analyses were performed comparing toxicity following cycles A and B in the 11 patients receiving 1.5 mg/m 2 topotecan (Tables 2a and b,  footnotes 1-5 and Table 3 ). The incidence of fever (P -0.06, 0 of 30 vs. 5 of 30) and grade 4 thrombocytopenia (P = 0.07, 4 of 30 vs. 11 of 30) as well as the need for platelet transfusions (P -0.06, 2 of 30 vs. 8 of 30) were borderline significantly less frequent after cycles A compared to cycles B. The next treatment cycle had to be postponed after 60% of cycles A compared to 13% of cycles B (P = 0.001) ( Table 3) .
Non-hematological toxicity
Generally, non-hematological toxicity was manageable and mild, i.e., mainly grade 1 and 2 (Table 4) . Seven cases of grade 3 or 4 toxicities were recorded. One episode of grade 3 and 4 hypomagnesemia, respectively, followed cycles B. One patient experienced grade 3 haematuria after the first cycle of topotecan-cisplatin.
T d l e 20.
Neutrophil counts a t nadir In this patient, the bladder mucosa appeared normal without evidence of bladder stones as judged by cystoscopy, but a small lesion in the mucosa of the urethra was observed. The patient was retreated with topotecancisplatin in cycles 3 and 5 according to the protocol and haematuria did not reappear. One patient was taken off study after three cycles of therapy due to a decrease in renal function. Prior to treatment 51
Cr-EDTA clearance was 78 ml/min which decreased to 46 ml/min. One patient entered at dose level 1.25 mg/m 2 experienced an episode of grade 3 constipation after the fourth treatment cycle including vincristine. The patient refused cycle 6 to avoid the reappearance of constipation. One case of grade 3 diarrhea and one case of grade 3 nausea followed cycle A and B, respectively.
Efficacy
Tumor responses were evaluated after every second treatment cycle. Overall 18 (86%, 95% confidence interval (95% CI): 64%-97%) had a response with 11 (52%, 95% CI: 30%-74%) and 7 (33%, 95% CI: 15%-57%) experiencing partial and complete responses, respectively. Three patients had progressive disease during treatment (n -2, dose level 1.0 mg/m 2 ; n = 1, dose level 1.5 mg/m 2 ). One of these patients treated at dose level 1.0 mg/m 2 presented with brain metastases and suffered an early death after receiving his first cycle of treatment. Death occurred at day 25 and was preceded by haematologic recovery but the patient had deterioration in brain metastases related symptoms including frank psychosis. Intracranial responses were observed in two out of three patients presenting with brain metastases.
Discussion
Topotecan is among the most active new chemotherapeutic agents in SCLC. Its activity with respect to tumor response and survival has proven to be at least equal to standard treatment in relapsed SCLC [19] . Further, topotecan and cisplatin in combination display synergy in preclinical model systems. Focus has been on a five-day topotecan schedule preceded by single-dose cisplatin on However, severe toxicity including treatment related deaths has been reported using this schedule [10] [11] [12] 20] . The current study is the first to report the MTD of the alternate schedule, i.e., five-day topotecan with single dose cisplatin on day 5. Out of 11 patients treated at 1.5 mg/m 2 no patients experienced DLT defining the MTD as 1.5 mg/m 2 which corresponds to the recommended single-agent dose of topotecan. A previous study has evaluated the sequence of topotecan and cisplatin [12] . Treatment cycles alternated between cisplatin given on day 1 and 5 in each individual patient with the aim of determining the MTD of topotecan in combination with cisplatin on day 1. Similar to the present study, they found no episodes of grade 4 neutropenia at the two lowest dose levels tested (0.75 and 1.0 mg/m 2 ), but grade 4 thrombocytopenia appeared at dose level 1.0 mg/m 2 . Both mean neutrophil and platelet counts were comparable to the figures reported here.
It is important to emphasize that the definition of DLT used in this study accepted a rather long duration of grade 4 neutropenia (> 7 days). Further, only episodes occurring following the first course of topotecancisplatin were included in the definition of DLT and thus only first course toxicity had implications for decisions regarding dose escalation. In fact, in subsequent cycles grade 4 thrombocytopenia and prolonged neutropenia were recorded even at dose level 1.0 and 1.25 mg/m 2 . At 1.5 mg/m 2 grade 4 thrombocytopenia and prolonged neutropenia were seen in 4 of 30 and 3 of 30 cycles, respectively (Tables 2a and b) . In a single-agent topotecan study, Rowinsky reported that the onset of nadir occurred as early as day 8-12 [21] , indicating that the duration of nadir could be underestimated in the present study as blood samples were drawn at day 11 and 15. Patients treated at 1.5 mg/m 2 seemed to tolerate cycles B better than all other cohorts as they achieved the highest mean nadir counts, possible reflecting that all 11 patients had limited disease and most had performance status one. Thus, the recommended dose of 1.5 mg/m 2 should be used with caution in patients who display features that could influence their tolerance to chemotherapy.
The severity of both thrombocytopenia and anemia increased as more cycles were administered. This is in contrast to the non-cumulative toxicity of single agent topotecan as well as topotecan in combination with cisplatin (except for one case of progressive anemia [10] ). Presumably, the cumulative toxicity is due to an interaction with the alternating cycles B and carboplatin is a plausible drug candidate for this effect as thrombocytopenia is a prominent feature of the toxicity profile of carboplatin. A progressive impairment of renal functions resulting in increased exposure to topotecan is a less likely explanation as neutropenia did not increase as more cycles were administered.
The alternate cycle B consisting of teniposide, carboplatin, cisplatin and vincristine was part of one of the arms in the most recent randomized study for the treatment of limited and extensive disease SCLC at the participating institutions [13] . Accordingly, it was relevant to compare toxicity of the two alternating cycles A and B. It seems that the toxicity of topotecan/cisplatin at the MTD is no more severe than that of cycle B. On the contrary, there was a tendency towards more severe thrombocytopenia following cycles B requiring more platelet transfusions. These data should however be interpreted with caution due to the small sample size. Failure to retreat at the planned day were significantly more common following cycles A than cycles B. This difference reflects that treatment intervals were 21 days and 28 days for cycles A and B, respectively. In 60% of cycles A, the next cycle had to be postponed due to low neutrophil counts at day 21. Similarly, Miller reported that only in 27% of cycles, retreatment could be administered at the planned 21-day interval using a schedule with cisplatin given on day 1 [10] . Thus, it appears that adding cisplatin either before or after topotecan hampers the feasibility of 21 days treatment intervals.
Non-hematological toxicity was mild with alopecia, fatigue, nausea, and peripheral neuropathy among the most frequent (Table 4) . No episodes of sepsis or treatment related deaths were recorded. As haemorragic cystitis were found to be dose limiting in the early trials of the parent compound camptothecin [1, 2] , we thoroughly investigated one case of grade 3 haematuria. No endoscopic evidence of cystitis was observed and the incidence did not reappear upon retreatment.
Tumor response rates were similar to that expected in this disease entity but the small number of patients including patients with both limited and extensive disease impede meaningful conclusions with respect to the efficacy of the regimen.
The present study indicates that topotecan with cisplatin on day 5 is tolerated in approximately double the recommended dose for topotecan when given in combination with cisplatin on day 1 in chemotherapy-naive patients [20] . Thus, toxicity of this drug combination is highly sequence dependent. Similar observations have been reported previously by Rowinsky et al. [12] who proposed that the increased toxicity of cisplatin preceding topotecan could be caused by a decrease in renal excretion of topotecan due to subclinical cisplatin induced nephrotoxicity. This notion was based on pharmacokinetic data indicating that administration of cisplatin on day 1 seemingly increased systemic exposure to topotecan. However, analyses were performed on a quite small sample size. Alternatively, the sequence dependence could be a result of various cellular mechanisms. A role for topoisomerase I in DNA repair has been suggested and camptothecin has been reported to inhibit DNA repair [22] . Thus, topotecan might inhibit the repair of cisplatin induced DNA damage. Indeed, in cultured tumor cells, 9-amino-camptothecin slows down the reversal of cisplatin induced DNA inter-strand cross-links [23] . Further, the lethality of topoisomerase I mediated cleavable complexes is highly dependent on active DNA replication [5] . Thus, hypothetically, upregulation of DNA replication in association with cellular repair of cisplatin induced DNA adducts might make cells more susceptible to topotecan induced cleavable complexes. Irrespective of the mechanism behind the pronounced sequence dependence, the main goal is to achieve the maximal tumor response and ultimately optimal survival with a manageable level of myelotoxicity. The data available to date can not determine which sequence is the optimal. It appears that cisplatin preceding topotecan leads to synergistic bone marrow cytotoxicity whereas this is not the case when cisplatin is delivered after topotecan. It is an open question whether the cytotoxicity on tumor cells is also sequence dependent, and thus it would be difficult at present to favor one sequence over the other. Of major concern is however the reported toxic deaths on the cisplatinbefore-topotecan schedule [11] . Further, the low doses of topotecan on the cisplatin-before-topotecan schedule might result in insufficient delivery of topotecan. Based on these considerations we plan to further explore the cisplatin-after-topotecan schedule. This will include studying the feasibility of incorporating concomitant radiotherapy. The future role of this strategy needs to be evaluated in large comparative randomized trials using survival as primary end-point.
